All News

PSA2L.jpg

The Top 10 Research Priorities in Psoriatic Arthritis

Jack Cush, MD

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Jack Cush, MD

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Read Article
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Jack Cush, MD

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article
infusion.biologic.jpg

RECITAL Trial: RTX vs. CTX in CTD-ILD

Jack Cush, MD

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
230px-Sjogren_syndrome_%282%29.jpg

Low Dose IL-2 Therapy in Sjögren’s

Jack Cush, MD

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Jack Cush, MD

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.

Read Article
scale decision balance question

The disconnect between objective inflammatory response and PROs in AxSpA

Antoni Chan, MD, PhD

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment.

Read Article
together solution

A Multidimensional Approach in the Management of Axial Spondylarthritis

Akhil Sood, MD

There has been much focus on the pharmacologic management of axSpA. Despite optimal control of inflammation, symptoms of fatigue and pain can persist. Long term use of analgesics including opioids carries significant risks. Strategies to improve response to treatment in this population is critical.

Read Article
lupus SLE

Dual target blockade may be better than one in SLE

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus. However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials have been inconsistent.

Read Article
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5

Links:

Dr. John Cush RheumNow ( View Tweet)
To Switch or Not: Biosimilars in Inflammatory Arthritis Dr. Jonathan Kay reports on abstract 1112 at #ACR22 Convergence. https://t.co/nrsH7yB7wu https://t.co/TngS4Kk6YK

Links:

Dr. John Cush RheumNow ( View Tweet)
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE
Olga Petryna DrPetryna ( View Tweet)
L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj
Eric Dein ericdeinmd ( View Tweet)
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

Links:

Richard Conway RichardPAConway ( View Tweet)
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz

Links:

Richard Conway RichardPAConway ( View Tweet)
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Baker et al, Corevitas registry in 7000+ RA pts Pts w/ moderate pain HR 1.37 Pts w/ severe pain HR 1.42 more likely to switch to diff MOA b/tsDMARD Adjusted for confounders incl DA Time we address pain separately to spare MAOs in a lifelong disease! Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m
Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×